{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-009253","form_type":"8-K","ticker":"PASG","cik":"0001787297","company_name":"Passage BIO, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.578727+00:00","generated_at":"2026-06-15T04:31:08.289630+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Passage Bio reports Q1 2023 net loss of $34.3M; cash runway into H1 2025","bullets":["Cash, cash equivalents and marketable securities $167.8M as of March 31, 2023, down from $267.1M a year ago; expected to fund operations into first half 2025.","Net loss $34.3M ($0.63 per share) for Q1 2023, compared to $42.8M ($0.79 per share) in Q1 2022.","R&D expenses $16.8M, down from $26.2M YoY; G&A expenses $19.0M, up from $15.1M due to non-recurring Catalent amendment costs.","On track to report interim clinical data for PBGM01 (GM1 gangliosidosis) and PBFT02 (FTD) in 2023; protocol amendment submitted for higher dose of PBGM01.","Initiated fourth global trial site for upliFT-D trial; expect to dose first patient at Dose 3 in second half 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-009253","json":"https://secwatch.observer/filing/0001558370-23-009253.json","markdown":"https://secwatch.observer/filing/0001558370-23-009253.md","text":"https://secwatch.observer/filing/0001558370-23-009253.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023009253/0001558370-23-009253-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023009253/pasg-20230511x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:31:08.289630+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e439290a36eaab77e100fa8b4551ddb21387b064","claim":"Passage BIO, Inc. reported the quarter ended March 31, 2023 results: net income $34.3 million, EPS $0.63 per basic and diluted share.","evidence_excerpt":"Net loss was $34.3 million, or a net loss of $0.63 per basic and diluted share, for the quarter ended March 31, 2023, compared to $42.8 million, or a net loss of $0.79 per basic and diluted share, for the same quarter in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787297/000155837023009253/0001558370-23-009253-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Net income","value":"$34.3 million"},{"label":"EPS","value":"$0.63 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}